236 related articles for article (PubMed ID: 30593627)
1. Studying the Hepatitis C Virus-Induced Epigenetic Signature After Cure with Direct-Acting Antivirals.
Perez S; Gal-Tanamy M
Methods Mol Biol; 2019; 1911():191-207. PubMed ID: 30593627
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.
Perez S; Kaspi A; Domovitz T; Davidovich A; Lavi-Itzkovitz A; Meirson T; Alison Holmes J; Dai CY; Huang CF; Chung RT; Nimer A; El-Osta A; Yaari G; Stemmer SM; Yu ML; Haviv I; Gal-Tanamy M
PLoS Genet; 2019 Jun; 15(6):e1008181. PubMed ID: 31216276
[TBL] [Abstract][Full Text] [Related]
3. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
Hamdane N; Jühling F; Crouchet E; El Saghire H; Thumann C; Oudot MA; Bandiera S; Saviano A; Ponsolles C; Roca Suarez AA; Li S; Fujiwara N; Ono A; Davidson I; Bardeesy N; Schmidl C; Bock C; Schuster C; Lupberger J; Habersetzer F; Doffoël M; Piardi T; Sommacale D; Imamura M; Uchida T; Ohdan H; Aikata H; Chayama K; Boldanova T; Pessaux P; Fuchs BC; Hoshida Y; Zeisel MB; Duong FHT; Baumert TF
Gastroenterology; 2019 Jun; 156(8):2313-2329.e7. PubMed ID: 30836093
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virus.
Takeda H; Takai A; Iguchi E; Mishima M; Arasawa S; Kumagai K; Eso Y; Shimizu T; Takahashi K; Ueda Y; Taura K; Hatano E; Iijima H; Aoyagi H; Aizaki H; Marusawa H; Wakita T; Seno H
Carcinogenesis; 2021 May; 42(5):672-684. PubMed ID: 33617626
[TBL] [Abstract][Full Text] [Related]
5. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?
Ioannou GN; Feld JJ
Gastroenterology; 2019 Jan; 156(2):446-460.e2. PubMed ID: 30367836
[TBL] [Abstract][Full Text] [Related]
6. Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis.
Virzì A; Roca Suarez AA; Baumert TF; Lupberger J
Cold Spring Harb Perspect Med; 2020 Jan; 10(1):. PubMed ID: 31501266
[TBL] [Abstract][Full Text] [Related]
7. Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients.
Cucchetti A; D'Amico G; Trevisani F; Morelli MC; Vitale A; Pinna AD; Cescon M;
Dig Liver Dis; 2018 Feb; 50(2):156-162. PubMed ID: 29102521
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation.
Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Otsuka S; Ohnami S; Nagashima T; Hatakeyama K; Kakuda Y; Sugino T; Urakami K; Akiyama Y; Yamaguchi K
Cancer Med; 2022 Apr; 11(8):1769-1786. PubMed ID: 35174643
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
Beste LA; Green PK; Berry K; Kogut MJ; Allison SK; Ioannou GN
J Hepatol; 2017 Jul; 67(1):32-39. PubMed ID: 28267622
[TBL] [Abstract][Full Text] [Related]
11. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation.
Kanda T; Lau GKK; Wei L; Moriyama M; Yu ML; Chuang WL; Ibrahim A; Lesmana CRA; Sollano J; Kumar M; Jindal A; Sharma BC; Hamid SS; Kadir Dokmeci A; Mamun-Al-Mahtab ; McCaughan GW; Wasim J; Crawford DHG; Kao JH; Ooka Y; Yokosuka O; Sarin SK; Omata M
Hepatol Int; 2019 Nov; 13(6):649-661. PubMed ID: 31541423
[TBL] [Abstract][Full Text] [Related]
12. Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.
Ooka Y; Miho K; Shuntaro O; Nakamura M; Ogasawara S; Suzuki E; Yasui S; Chiba T; Arai M; Kanda T; Maruyama H; Yokosuka O; Kato N; Mochizuki H; Omata M
Hepatol Int; 2018 Nov; 12(6):523-530. PubMed ID: 30242733
[TBL] [Abstract][Full Text] [Related]
13. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma.
Vescovo T; Refolo G; Vitagliano G; Fimia GM; Piacentini M
Clin Microbiol Infect; 2016 Oct; 22(10):853-861. PubMed ID: 27476823
[TBL] [Abstract][Full Text] [Related]
15. Reverse inflammaging: Long-term effects of HCV cure on biological age.
Oltmanns C; Liu Z; Mischke J; Tauwaldt J; Mekonnen YA; Urbanek-Quaing M; Debarry J; Maasoumy B; Wedemeyer H; Kraft ARM; Xu CJ; Cornberg M
J Hepatol; 2023 Jan; 78(1):90-98. PubMed ID: 36152762
[TBL] [Abstract][Full Text] [Related]
16. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.
He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ
Aliment Pharmacol Ther; 2020 Jan; 51(1):34-52. PubMed ID: 31808566
[TBL] [Abstract][Full Text] [Related]
17. Chitinase 3-like-1, Tolloid-like protein 1, and intergenic gene polymorphisms are predictors for hepatocellular carcinoma development after hepatitis C virus eradication by direct-acting antivirals.
Mangoud NOM; Ali SA; El Kassas M; Soror SH
IUBMB Life; 2021 Feb; 73(2):474-482. PubMed ID: 33347699
[TBL] [Abstract][Full Text] [Related]
18. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
[TBL] [Abstract][Full Text] [Related]
19. Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance.
Hlady RA; Zhao X; El Khoury LY; Luna A; Pham K; Wu Q; Lee JH; Pyrsopoulos NT; Liu C; Robertson KD
Hepatology; 2022 Apr; 75(4):983-996. PubMed ID: 34387871
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip.
Goto K; Roca Suarez AA; Wrensch F; Baumert TF; Lupberger J
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
